Repligen to Report Initial Results of Phase 2 Clinical Trial Conference Call and Web Cast Invitation

Apr 03, 2001, 01:00 ET from Repligen Corporation

    NEEDHAM, Mass., April 3 /PRNewswire/ -- Repligen Corporation
 (Nasdaq:   RGEN) announced today that the Company President and Chief Executive
 Officer Dr. Walter C. Herlihy will host a conference call on Wednesday April
 4, 2001 to report the initial results of the Phase 2 Clinical Trial of
 Secretin in Autism.  Please access the call at 8:55 a.m. EST on Wednesday
 April 4, 2001 via the internet at
 http://www.vcall.com/NASApp/VCall/EventPage?ID=71845 or via the Repligen web
 site at www.repligen.com.  If you are unable to access the webcast via the
 internet, you can also listen to the broadcast by calling 1-800-289-0462.
     To listen to the webcast via the internet, please go to the web site at
 least fifteen minutes early to register, download, and if necessary install
 Real Player audio software.  For those who cannot listen to the live
 broadcast, a replay will be available shortly after the call on the Company's
 web site at www.repligen.com for 90 days.
     Repligen Corporation develops new drugs for debilitating pediatric
 disorders including autism, cancer, and immune and metabolic disorders.
 Repligen also manufactures and markets a set of patented products based on
 Protein A, which are used by the pharmaceutical industry to produce
 therapeutic antibodies.  Its corporate headquarters are located at 117 Fourth
 Avenue, Needham MA, 02494.  Additional information may be requested from
 www.repligen.com.
 
     This press release contains forward-looking statements based on current
 management expectations.  There are certain key factors which could cause
 future results to differ materially from those anticipated by management.
 Such factors include, but are not limited to: uncertainty in the realization
 of future revenues, the uncertain timelines for clinical activity, required
 regulatory approvals, results of pending or future clinical trials, Repligen's
 ability to continue to establish collaborative arrangements with third
 parties; Repligen's ability to maintain financial stability; the technical
 risks associated with development and manufacture of clinical products; the
 fact that there can be no assurances that patents relating to the Repligen's
 potential products will afford adequate protection to  Repligen, the risks of
 technological change and competition, and the competitive environment of the
 biotechnology and pharmaceutical industries.  These factors are more fully
 discussed in Repligen's periodic filings with the Securities and Exchange
 Commission.
 
 

SOURCE Repligen Corporation
    NEEDHAM, Mass., April 3 /PRNewswire/ -- Repligen Corporation
 (Nasdaq:   RGEN) announced today that the Company President and Chief Executive
 Officer Dr. Walter C. Herlihy will host a conference call on Wednesday April
 4, 2001 to report the initial results of the Phase 2 Clinical Trial of
 Secretin in Autism.  Please access the call at 8:55 a.m. EST on Wednesday
 April 4, 2001 via the internet at
 http://www.vcall.com/NASApp/VCall/EventPage?ID=71845 or via the Repligen web
 site at www.repligen.com.  If you are unable to access the webcast via the
 internet, you can also listen to the broadcast by calling 1-800-289-0462.
     To listen to the webcast via the internet, please go to the web site at
 least fifteen minutes early to register, download, and if necessary install
 Real Player audio software.  For those who cannot listen to the live
 broadcast, a replay will be available shortly after the call on the Company's
 web site at www.repligen.com for 90 days.
     Repligen Corporation develops new drugs for debilitating pediatric
 disorders including autism, cancer, and immune and metabolic disorders.
 Repligen also manufactures and markets a set of patented products based on
 Protein A, which are used by the pharmaceutical industry to produce
 therapeutic antibodies.  Its corporate headquarters are located at 117 Fourth
 Avenue, Needham MA, 02494.  Additional information may be requested from
 www.repligen.com.
 
     This press release contains forward-looking statements based on current
 management expectations.  There are certain key factors which could cause
 future results to differ materially from those anticipated by management.
 Such factors include, but are not limited to: uncertainty in the realization
 of future revenues, the uncertain timelines for clinical activity, required
 regulatory approvals, results of pending or future clinical trials, Repligen's
 ability to continue to establish collaborative arrangements with third
 parties; Repligen's ability to maintain financial stability; the technical
 risks associated with development and manufacture of clinical products; the
 fact that there can be no assurances that patents relating to the Repligen's
 potential products will afford adequate protection to  Repligen, the risks of
 technological change and competition, and the competitive environment of the
 biotechnology and pharmaceutical industries.  These factors are more fully
 discussed in Repligen's periodic filings with the Securities and Exchange
 Commission.
 
 SOURCE  Repligen Corporation